10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

# SERINC2 Antibody

Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP50605

## Product Information

| | |
|---|---|
| **Application** | WB, IF |
| **Primary Accession** | Q96SA4 |
| **Reactivity** | Human, Mouse, Rat |
| **Host** | Rabbit |
| **Clonality** | polyclonal |
| **Calculated MW** | 50742 |

## Additional Information

| | |
|---|---|
| **Gene ID** | 347735 |
| **Other Names** | Serine incorporator 2, Tumor differentially expressed protein 2-like, SERINC2, TDE2L |
| **Dilution** | WB~~ 1:1000 IF~~1:100 |
| **Format** | Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.09% (W/V) sodium azide and 50% glycerol. |
| **Storage Conditions** | -20℃ |

## Protein Information


| | |
|---|---|
| **Name** | SERINC2 ( HGNC:23231) |
| **Synonyms** | TDE2L |
| **Function** | Non-ATP-dependent, non-specific lipid transporter for phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. Functions as a scramblase that flips lipids in both directions across the membrane. In contrast to SERINC3 and SERINC5, has no effect on HIV- 1 particles infectivity. |
| **Cellular Location** | Cell membrane; Multi-pass membrane protein |

## References


Wang Y.-G.,et al.Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
Li N.,et al.Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
Clark H.F.,et al.Genome Res. 13:2265-2270(2003).

Ota T.,et al.Nat. Genet. 36:40-45(2004).
Gregory S.G.,et al.Nature 441:315-321(2006).

## Images




Western blot analysis of lysates from Hela,HepG2 cell line (from left to right),using SERINC2 Antibody(AP50605). AP50605 was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:5000 dilution was used as the secondary antibody.Lysates at 35ug per lane.



Immunofluorescence analysis of NIH/3T3 cells, using SERC2 antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.